Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

Item does not contain fulltextBACKGROUND: In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. OBJECTIVE: To evaluate the long-term safety of etanercept in an open-label extension study for up to 72 weeks in patients with moderate-to-severe plaque psoriasis. METHODS: A total of 912 patients received 50 mg subcutaneous etanercept once weekly (OW) for the first 12 weeks of this extension study. Thereafter, eligible patients could maintain the 50 mg QW dose (n = 321) or escalate to 50 mg twice weekly (BIW; n = 591) anytime thereafter based on one of three predetermined criteria. RESULTS: Etanercept was well tolerated during 1056 patient-years of exposure; no difference was observed between the 50 mg QW and 50 mg BIW dosages in rates of adverse events and infections. Improvement in skin disease was maintained throughout the study. Patients who stopped and then restarted etanercept also showed improvement in psoriasis. CONCLUSION: Psoriatic patients continued to benefit from open-label etanercept treatment, both continuous and interrupted therapy, which was generally well tolerated after a combined 2.5 years of experience.1 augustus 201

Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

BACKGROUND: In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. OBJECTIVE: To evaluate the long-term safety of etanercept in an open-label extension study for up to 72 weeks in patients with moderate-to-severe plaque psoriasis. METHODS: A total of 912 patients received 50 mg subcutaneous etanercept once weekly (OW) for the first 12 weeks of this extension study. Thereafter, eligible patients could maintain the 50 mg QW dose (n = 321) or escalate to 50 mg twice weekly (BIW; n = 591) anytime thereafter based on one of three predetermined criteria. RESULTS: Etanercept was well tolerated during 1056 patient-years of exposure; no difference was observed between the 50 mg QW and 50 mg BIW dosages in rates of adverse events and infections. Improvement in skin disease was maintained throughout the study. Patients who stopped and then restarted etanercept also showed improvement in psoriasis. CONCLUSION: Psoriatic patients continued to benefit from open-label etanercept treatment, both continuous and interrupted therapy, which was generally well tolerated after a combined 2.5 years of experience

Onychomycosis: diagnosis and definition of cure.

Until now, there has been no agreement on criteria defining resolution of onychomycosis. Most published reports use clinical and mycological cure, which comprises a completely normal-appearing nail plate, and negative nail culture and microscopy results, as the end point for defining success of therapeutic intervention. Reported here is the definition of onychomycosis, which delineates both primary and secondary criteria for diagnosis of onychomycosis and identifies clinical and laboratory parameters to define a resolved fungal nail infection. Onychomycosis cure is defined by the absence of clinical signs or the presence of negative nail culture and/or microscopy results with one or more of the following minor clinical signs: (1) minimal distal subungual hyperkeratosis; and (2) nail-plate thickening. Clinical signs indicative of persistent onychomycosis at the end of the observation period include (1) white/yellow or orange/brown streaks or patches in or beneath the nail plate; and (2) lateral onycholysis with subungual debris. Although nail appearance will usually continue to improve after cessation of therapy, the nails may have a persistent abnormal appearance even in cases where treatment has been effectiv

Onychomycosis by Scytalidium dimidiatum: report of two cases in Santa Catarina, Brazil Onicomicose por Scytalidium dimidiatum: relato de dois casos em Santa Catarina, Brasil

Onychomycoses constitute pathologies frequently seen in dermatological practice worldwide. Usually, they are caused by two groups of pathogenic fungi: dermatophytes and yeasts of the Candida genus. However, in a small fraction of the cases, the etiologic agents comprise nondermatophyte molds, belonging to several genera and species. The objective of this study was to present two cases of onychomycosis associated to the mold Scytalidium dimidiatum in patients residing in two cities of Santa Catarina State, Brazil. Aspects of fungal pathogenesis, as well as the epidemiological characteristics and laboratory diagnosis, are discussed.<br>Onicomicoses se apresentam como infecções fúngicas localizadas, muito freqüentes na prática dermatológica. Na grande maioria das vezes, são causadas por dois grupos: dermatófitos e leveduras do gênero Candida. Entretanto, em um pequeno percentual dos casos, os agentes etiológicos compreendem fungos filamentosos não-dermatófitos, pertencentes a vários gêneros e espécies. O objetivo deste trabalho foi o de apresentar dois casos de onicomicose associados à espécie Scytalidium dimidiatum em pacientes residentes em dois municípios do estado de Santa Catarina, Brasil. São discutidos aspectos relacionados a sua patogênese, epidemiologia, diagnóstico laboratorial e tratamento

A ten-year survey of onychomycosis in the Central Region of the Rio Grande do Sul, Brazil Um estudo de 10 anos sobre onicomicoses na região central do Rio Grande do Sul, Brasil

Onychomycosis is a common infection of the nail plate caused by fungal microrganisms, and represents approximately 50% of nails disorders and 30% of all superficial mycotic infections. We present a study of the frequency, epidemiology and clinical aspects of onychomycosis in the central region of Rio Grande do Sul during the period 1988-1997.<br>Onicomicoses são infecções comuns da lâmina ungueal causadas por fungos filamentosos e leveduras, que representam aproximadamente 50% das alterações das unhas e 30% de todas as infecções fúngicas superficiais. Apresentamos um estudo sobre a freqüência, epidemiologia e aspectos clínicos das onicomicoses na região central do Rio Grande do Sul durante o período 1988-1997